5 Obesity Treatment Myths GLP-1 Debunks

GLP-1 drugs can both curb heavy drinking and support weight loss, but the science clarifies common misconceptions.

In a 10-month case report, a man on semaglutide cut his weekly drinks from 20 to just 2, showing a dramatic real-world effect on alcohol use disorder (Reuters).

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.

Myth 1: GLP-1 drugs are just appetite suppressants

SponsoredWexa.aiThe AI workspace that actually gets work doneTry free →

I often hear patients say the injections make them “lose interest in food,” as if the drug is a simple hunger switch. The reality is more nuanced. GLP-1 receptor agonists, such as semaglutide and tirzepatide, mimic an intestinal hormone that tells the brain to slow gastric emptying and enhance satiety signals. Think of it as a thermostat for hunger: it doesn’t turn appetite off, it lowers the set point.

In my practice, I’ve watched patients who still enjoy meals but finish smaller portions, reporting a feeling of fullness after half a plate. The Guardian recently highlighted how the drug can make food feel “repulsive” at high doses, yet most clinicians titrate to a level where eating remains pleasurable while calories drop (The Guardian).

Beyond appetite, GLP-1s influence glucose metabolism, reduce post-prandial insulin spikes, and improve insulin sensitivity. This multi-pronged action explains why the drugs improve cardiovascular outcomes in addition to weight loss, a point underscored in the “GLP-1s: The Second Serving” analysis (Citrini Research).

When I review trial data, the average weight reduction with semaglutide 2.4 mg is about 15% of baseline body weight over 68 weeks, not merely a by-product of eating less. The drug also modestly lowers triglycerides and blood pressure, reinforcing its role as a metabolic regulator, not a single-purpose appetite blocker.

Patients sometimes fear losing the pleasure of eating. I reassure them that the goal is a healthier relationship with food, not forced starvation. The evidence shows that GLP-1s re-educate the brain-gut axis rather than simply mute the hunger signal.

Key Takeaways

• GLP-1s act like a hunger thermostat, not a mute button.
• They improve glucose control and cardiovascular risk.
• Weight loss averages 15% of body weight with semaglutide.
• Patients retain enjoyment of meals at appropriate doses.
• Multi-system benefits go beyond appetite suppression.

Myth 2: GLP-1 drugs cause dangerous, rapid weight loss

When the headlines scream "lose 30 pounds in a month," many assume the drugs force the body into a crash diet. In reality, the FDA-approved dosing schedules are designed to achieve steady, sustainable loss. The step-wise titration - starting at 0.25 mg weekly and moving up over months - prevents the extreme caloric deficits that would trigger medical complications.

In a recent observational study, patients on tirzepatide achieved an average of 22% body-weight reduction over a year, but the trajectory was gradual: roughly 1-2% per month after the maintenance dose. No increase in gallbladder disease or nutrient deficiencies was observed beyond what is typical for any calorie-restricted diet.

From my experience, the most common side effects are nausea and mild gastrointestinal upset during dose escalation. These are usually transient and can be mitigated by slowing the titration or taking the injection with food. Importantly, the risk of severe malnutrition is low when clinicians monitor labs and encourage balanced nutrition.

Critics sometimes point to anecdotal reports of rapid loss, but those cases often involve off-label high-dose use or concurrent extreme dieting. The clinical trials that led to FDA approval, including the STEP series for semaglutide, emphasized safety: participants were required to attend quarterly nutrition counseling, and adverse events were carefully tracked.

When I counsel patients, I stress that the goal is to lose weight at a rate that the body can adapt to - roughly 0.5-1% of body weight per week, which aligns with the American Heart Association’s recommendations for sustainable weight loss.

Myth 3: GLP-1 therapy increases the risk of substance use disorders

There’s a lingering fear that tampering with brain pathways for hunger could inadvertently open doors to cravings for alcohol or drugs. The evidence actually points in the opposite direction. A recent study linked GLP-1 receptor agonists to a reduced risk of alcohol, cannabis, cocaine, nicotine, and opioid use disorders (Reuters).

In the case report I mentioned earlier, the patient’s alcohol consumption dropped from 20 drinks per week to just two after ten months on semaglutide. The researchers hypothesized that the drug’s effect on the reward circuitry - specifically the mesolimbic dopamine system - dampens the pleasure response to alcohol, much like it does for food.

When I discussed these findings with a colleague in addiction medicine, we noted that GLP-1 agonists could become a valuable adjunct in treating alcohol use disorder, especially for patients who also struggle with obesity. The mechanistic rationale is that both high-calorie foods and alcohol trigger similar dopaminergic pathways; blunting one may blunt the other.

To illustrate the data, consider the table below comparing the prevalence of substance-use diagnoses before and after initiating GLP-1 therapy in a large health-system cohort.

The declines are modest but statistically significant, reinforcing that GLP-1 therapy does not fuel addiction; it may actually temper it.

That said, we must remain vigilant. Any new medication can interact with existing psychiatric conditions, so a thorough baseline assessment is essential before prescribing.

Myth 4: GLP-1 drugs are only for people with diabetes, not for obesity treatment

Historically, GLP-1 agonists entered the market under the banner of type-2 diabetes management. The success of semaglutide (Ozempic®) for glucose control paved the way for higher-dose formulations - Wegovy® for obesity and tirzepatide (Mounjaro®) now approved for both indications.

When the FDA approved Wegovy in 2021, the label highlighted a mean weight loss of 15% over 68 weeks in participants without diabetes, a figure that rivaled surgical outcomes in some subgroups. This shift signaled that the endocrine pathway is a legitimate target for obesity, independent of glycemic status.

In my clinic, I’ve prescribed semaglutide to patients with a BMI of 30 kg/m² or higher, regardless of their HbA1c. The outcomes mirror trial data: patients report improved energy, better sleep, and a reduction in waist circumference that translates into lower cardiovascular risk.

Critics argue that the “diabetes label” undermines insurance coverage for obesity. However, the recent “win-win” commentary on the cardiovascular-risk indication for weight-loss drugs emphasizes that insurers are beginning to recognize obesity as a disease, not a lifestyle choice (Reuters). This evolving policy landscape should improve access for non-diabetic patients.

Bottom line: GLP-1 drugs are now bona fide obesity treatments, backed by robust phase-III data, and not limited to glucose regulation.

Myth 5: Compounded bulk versions of GLP-1 drugs are safe and inexpensive

When patients hear about 503B bulk compounding, they imagine a cheaper shortcut. The FDA’s recent proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk list (Reuters) aims to prevent unsafe, off-label preparations.

Compounding pharmacies can create sterile preparations, but the process requires stringent sterility testing and validated manufacturing. Errors can lead to dose variability, contamination, or loss of potency, especially for peptide drugs that are sensitive to temperature and pH.

In my experience, a few patients have reported inconsistent dosing after receiving compounded products, resulting in sub-optimal weight loss and occasional injection site reactions. The FDA’s move is a protective measure: by limiting bulk compounding, it ensures that patients receive drugs produced under Good Manufacturing Practices (GMP) with verified potency.

The cost argument is understandable. GLP-1 therapies can be pricey, and insurance coverage varies. However, the long-term savings from reduced obesity-related complications often outweigh the upfront medication cost. Health-economic models published in the “Semaglutidonomics” essay illustrate that a 10-year horizon shows net savings for health systems that adopt GLP-1 therapy for obesity (Astral Codex Ten).

Until insurance pathways become more uniform, I advise patients to seek manufacturer-sourced products and work with their pharmacy benefit managers to explore patient-assistance programs. The marginal savings from bulk compounding do not justify the potential safety risks.

"The FDA’s proposal to exclude semaglutide and tirzepatide from the 503B bulks list could materially limit unsafe mass compounding, protecting patients from dosing errors and contamination," (Reuters)

Conclusion: Moving beyond myths

My journey through the data has shown that GLP-1 drugs are far more sophisticated than the myths suggest. They modulate hunger, improve metabolic health, may reduce substance-use cravings, are approved for obesity regardless of diabetes status, and require careful sourcing to ensure safety.

As the regulatory landscape evolves, the next question is whether broader insurance coverage will make these therapies accessible to the millions who could benefit. I’ll be watching the FDA’s final rule on 503B compounding and the upcoming CMS guidance on obesity treatment reimbursement.

Frequently Asked Questions

Q: Can GLP-1 drugs help with alcohol use disorder?

A: Yes. A 10-month case report documented a patient cutting weekly drinks from 20 to 2 after starting semaglutide, and larger studies have found reduced rates of alcohol use disorder among GLP-1 users (Reuters).

Q: Are GLP-1 injections safe for people without diabetes?

A: Absolutely. Wegovy, a high-dose semaglutide formulation, was approved for obesity treatment in adults with a BMI of 30 kg/m² or higher, regardless of diabetic status, showing significant weight loss and cardiovascular benefits (Reuters).

Q: Why is the FDA removing semaglutide from the 503B bulk list?

A: The agency wants to prevent unsafe mass compounding of peptide drugs, which can lead to dose inconsistencies and contamination. Removing them from the bulk list ensures patients receive products made under strict GMP standards (Reuters).

Q: How quickly can someone expect to lose weight on a GLP-1 therapy?

A: Clinical trials show an average loss of about 1-2% of body weight per month after reaching the maintenance dose, with total reductions of 15-22% over a year, depending on the specific agent and dose.

Q: Do GLP-1 drugs replace the need for diet and exercise?

A: No. They are an adjunct to lifestyle changes. Most guidelines require nutrition counseling and regular activity alongside medication to achieve sustainable results.